Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Phase 1

1(25.0%)

N/A

1(25.0%)

4Total

Phase 2(2)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07348042Phase 1Recruiting

Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors

Role: lead

NCT04931446Unknown

Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis

Role: lead

NCT04892615Unknown

he Safety Research of Timing of the Removal of Abdominal Drains After Pancreatic Surgery

Role: lead

NCT04704895Not ApplicableUnknown

Comparing Early Enteral Nutrition Versus Parenteral Nutrition After Pancreaticoduodenectomy

Role: lead

NCT04620577Unknown

The Influence of Antibiotics on the Incidence of Biliary Tract Infections After PTCD for Malignant Obstructive Jaundice

Role: lead

NCT02005419Phase 2Completed

Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

Role: lead

NCT02023021Phase 2Completed

Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

Role: lead

All 7 trials loaded